NCT04328467View on ClinicalTrials.gov

Pre-exposure Prophylaxis for SARS-Coronavirus-2

PHASE3CompletedINTERVENTIONAL
Enrollment

1,483

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

July 13, 2020

Study Completion Date

July 13, 2020

Conditions
COVID-19Corona Virus InfectionARDSAcute Respiratory Distress Syndrome
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine; 200mg tablet; oral

OTHER

Placebo

Placebo; tablet; oral

Trial Locations (2)

55455

Nationwide Enrollment via Internet, please email: [email protected], Minneapolis

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT04328467 - Pre-exposure Prophylaxis for SARS-Coronavirus-2 | Biotech Hunter | Biotech Hunter